Suchergebnisse - "Zamagni, Elena"

PubPharm (238)

1

Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients

enthalten in: Cells | 2024

von Borsi, E. | Vigliotta, I. | Poletti, A. | +19

2

Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain

enthalten in: European journal of haematology | 2024

von Lehne, M. | Kortüm, K. | Ramasamy, K. | +10

3

What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?

enthalten in: Haematologica | 2024

von Autore, F. | Bramanti, S. | Lessi, F. | +18

4

Belantamab mafodotin : an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

enthalten in: Haematologica | 2024

von Mateos, M. | Weisel, K. | Terpos, E. | +13

5

Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features

enthalten in: Nature communications | 2024

von Terragna, C. | Poletti, A. | Solli, V. | +17

6

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma : a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials

enthalten in: Haematologica | 2024

von Gentile, M. | Vigna, E. | Palmieri, S. | +44

7

Real‐world treatment patterns in patients initiating third‐line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain

enthalten in: European Journal of Haematology | 2024

von Lehne, M. | Kortüm, K. | Ramasamy, K. | +10

8

Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma : a challenging and happy ending fight

enthalten in: Leukemia research reports | 2024

von Ielo, C. | Fazio, F. | Rocchi, S. | +5

9

High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

enthalten in: Clinical and experimental medicine | 2023

von Borsi, E. | Mazzocchetti, G. | Dico, A. | +16

10

Difficult-to-treat patients with relapsed/refractory multiple myeloma : A review of clinical trial results

enthalten in: EJHaem | 2023

von Raab, M. | Zamagni, E. | Manier, S. | +3

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[24]